Enhancing Cardiovascular Health Through Active Folate Supplementation
The Global Burden of Cardiovascular Disease
Cardiovascular disease is among the greatest public health challenges of the 21st century. In developing countries, the burden of cardiovascular disease is consistently on the rise. Of the total number of women with coronary heart disease, the estimated number increased by 120% from 1990 to 2020, and by 137% for men during the same period. In Indonesia, the reported prevalence of heart disease was 30.8 percent, according to the 2023 National Health Survey (RISKESDAS). Cardiovascular disease (also known as heart disease) is a range of diseases, including coronary artery disease (CAD), cerebrovascular disease, and peripheral artery disease. Coronary heart disease is caused by reduced myocardial perfusion, leading to angina (chest pain) and myocardial infarction. Cerebrovascular disease is associated with stroke as well as transient ischemic attacks (also known as mini-strokes). Atherosclerosis, the accumulation of plaque in blood vessels, is one of the main causes of these cardiovascular conditions.
Atherosclerosis and Its Role in Cardiovascular Disease Pathogenesis
Atherosclerosis is an inflammatory disease of the arteries and is the primary cause of cardiovascular disease (CVD) and stroke. Atherosclerosis in individuals results in the narrowing of arteries due to lipid buildup and arterial inflammation, causing them to harden and impair blood flow, thereby depriving the heart or brain of oxygen. Without treatment over the long term, atherosclerosis may progress into coronary artery disease (CAD), the most prevalent type of cardiovascular disease (CVD). It may eventually lead to clinical complications, including myocardial infarction (MI) and stroke. Because it is a slowly progressive condition, atherosclerosis is most serious among elderly patients. Lesions or atherosclerotic plaques can occur due to multiple factors, such as:
The growth of this lesion will become more serious. It can cause > 50% or even more blood flow reduction, which could potentially cause a heart attack (angina) if physically active/exercised under stress. The lesion can become unstable and rupture, causing a wound that triggers blood clotting in the coronary artery. This plaque forms a clot that blocks blood flow to the heart, leading to myocardial infarction. The clot may leave the heart and migrate to the brain and, if not removed, trigger a stroke.
Stroke and Vascular Health
A stroke is a disease where a person is clinically suffering from a neurological deficit resulting from vascular injury (infarction or blockage and bleeding in the brain) of the central nervous system. Stroke is considered to be the second leading cause of death and disability globally. Stroke is not a single disease condition but, rather, caused by numerous risk factors and related complications arising from other underlying diseases such as diabetes, hypertension, and coronary heart disease. Strokes may also be labeled as ischemic or hemorrhagic strokes. Ischemic strokes result from a lack of or disruption of blood supply to a region in the brain and are the most common type of stroke. Hemorrhagic strokes are caused by bleeding in the brain due to a rupture of a blood vessel. Most (about 85%) strokes are caused by blockages in brain blood vessels, causing a lack of oxygen supply to the brain, a phenomenon referred to as ischemic stroke. Ischemic stroke is commonly caused by atherosclerosis of the small blood vessels in the brain, cardioembolism, and atherothromboembolism of the large blood vessels of the brain. Post-stroke patients are susceptible to other complications, particularly those resulting from brain injury itself, like disability, cognitive impairment, and neurological disorders.
Hyperhomocysteinemia in Cardiovascular Disease Pathogenesis
Homocysteine is from methionine. 5-MTHF, the active form of folate involved in the remethylation of homocysteine to methionine, participates in this remethylation; thus, its level is vital for maintaining normal homocysteine levels. This mechanism also participates in gene expression by mediating methylation reactions. Methionine metabolism is a one-carbon pathway that requires 5-MTHF (active folate), vitamin B6, and vitamin B12. But the balance of this metabolism can be disturbed through a lack of 5-MTHF (active folate). MTHFR polymorphism-associated genetic mutations and insufficient intake of folic acid from food sources or supplements can lead to folic acid deficiency. When the enzyme involved in homocysteine metabolism is disrupted, homocysteine can accumulate in the blood (hyperhomocysteinemia).
Cross-sectional studies showed that vitamin B levels should be increased and homocysteine levels reduced to prevent stroke. Hyperhomocysteinemia is a state where homocysteine increases significantly, and the concentration of homocysteine in the blood is out of the normal range of 5–15 mmol/L. Hyperhomocysteinemia is divided into 3 types: mild (15–30 mmol/L), moderate (30–100 mmol/L), and severe (>100 mmol/L). Hyperhomocysteine can lead to a variety of health problems. Untreated symptoms of this condition can lead to heart disease (atherosclerosis and stroke). This occurs as homocysteine toxicizes the endothelium of blood vessels, elevates LDL oxidation, and induces clotting.
Endothelial cells within blood vessels regulate blood circulation homeostasis and the walls of blood vessels, akin to gatekeepers of heart health. Endothelial cells are critical cellular players in maintaining blood vessel wall homeostasis, vascular tone, coagulation, inflammation, and permeability. Endothelial cells lining blood vessels in the circulatory system are at risk from multiple factors, leading to various pathological states, such as endothelial dysfunction and barrier disruption. Such damage can trigger domino effects on heart health, including inflammation responses, monocyte recruitment, plaque formation, alterations in heart structure and function, and thrombosis (formation of blood clots). Data from studies suggests that hyperhomocysteinemia leads to endothelial cell damage and endothelial dysfunction.
The proportionate concentration of homocysteine has been reported to be associated with atherosclerosis in multiple other studies. Plasma Hcy levels are substantially raised in patients with coronary artery disease compared to baseline controls with normal angiography. Clinical studies demonstrate that plasma Hcy levels can be greatly increased, and even if 12% above the upper normal (normal upper limit) limits have been associated with a 3.4-fold increase in the risk of myocardial infarction (heart attack).
A study published in the Journal of the American College of Cardiology (JACC) in 2024 found that homocysteine levels (tHcy) are positively associated with myocardial injury and cardiovascular mortality, further strengthening the link between HHcy and CVD events.
Another study by the International Renal Research Institute in Italy in 2017 found that 85% of patients with chronic kidney disease had hyperhomocysteinemia. This reinforces the association between hyperhomocysteinemia and an increased risk of cardiovascular disease and kidney damage.
Limitations of Dietary Folate and Conventional Folic Acid Supplementation
Folate is a naturally occurring nutrient, mainly in leafy green vegetables and whole grains; however, dietary intake alone is not enough for the greater physiological demand of pregnancy planning. In addition, synthetic folic acid is biologically inactive and must be metabolically activated before it can participate in folate-dependent pathways. This gradual step, however, requires enzymatic completion by dihydrofolate reductase (DHFR) and methylenetetrahydrofolate reductase (MTHFR) to produce the active form, 5-methyltetrahydrofolate (5-MTHF), by biological channels. Despite this, such conversion is intrinsically inefficient and highly heterogeneous at the individual level, especially for those exposed to common MTHFR polymorphisms (C677T and A1298C), which are widely prevalent. Affecting about 25% of the world’s population and 42% of people in Southeast Asia, these genetic variations have a major impact on those with reduced capacity to utilize folic acid effectively. Given that, traditional folic acid supplementation may produce fluctuating clinical response, described as:
These limitations highlight a critical gap in conventional folic acid supplementation, particularly in vascular cognitive health, where efficient folate metabolism is essential for maintaining neurochemical balance and optimal brain function. Conversely, biologically active folate (5-methyltetrahydrofolate, 5-MTHF) overcomes these limitations by bypassing enzymatic conversion, assuring immediate bioavailability and consistent cellular metabolic activity. Active folate establishes itself as a more predictable and efficient standard for folate supplementation by effectively restoring methylation capacity and finely controlling homocysteine balance, thereby offering a clinically applicable approach.
Clinical Evidence and Cardiovascular Outcomes
Folate supplementation has been effective in stroke prevention and blood pressure control by reducing hyperhomocysteinemia. One prospective clinical study conducted by Mazza, A. et al. in 2016 demonstrated a reduction in homocysteine levels of up to 55.8% with 5-MTHF (Active Folate) 400 mcg compared with baseline.
Another large-scale study, conducted in China involving more than 20,000 hypertensive patients, found that using folate in patients receiving antihypertensive therapy can significantly reduce the incidence of stroke and progressively reduce the risk of kidney function.
Evidence Based
The study by Huo, et. al. (2015), showed that folate administration in patients receiving antihypertensive therapy (n=10,348) can reduce the incidence:
The study by Xu, et. al. (2016), showed that folate administration in patients receiving antihypertensive therapy can reduce the incidence:
Clinical Applications and Target Populations
Biologically active folate (5-methyltetrahydrofolate, 5-MTHF) supplementation is a viable, mechanism-based therapy for cardiovascular disease in at-risk patients, including those with metabolic and genetic predispositions. Active folate directly promotes one-carbon metabolism, thereby contributing to optimal homocysteine homeostasis, endothelial function, and vascular integrity, thereby targeting major determinants of cardiovascular disease. One of the groups that might particularly benefit from active folate supplementation is:
In such populations, active folate is a beneficial metabolic modality that complements traditional therapies by targeting metabolic pathways and enhancing underlying biochemical processes and, in part, protects the vascular system by improving vascular and cardiac function and overall cardiovascular prognosis.
The Future of Folate Supplementation in Cardiovascular Health
Novel strategies in cardiovascular health are fundamentally changing the way nutrition can contribute to the prevention and control of disease, moving toward a more targeted, mechanism-driven approach rather than conventional supplementation. More recently, emerging evidence also indicates that favourable overall cardiovascular outcomes relate not only to nutrient intake alone but also to metabolic resource utilization, which is highly individual-dependent and influenced by genetic, enzymatic, and physiological variability. Part of this evolution is a greater understanding of folate-based metabolism, or the one-carbon metabolic pathway, which controls homocysteine clearance, methylation, endothelial performance, and circulation.
In particular, disruption of this pathway, such as impaired enzymatic conversion, genetic polymorphisms, or metabolic damage, has long been shown to be a modifiable determinant of cardiovascular risk. Biologically active folate (5-methyltetrahydrofolate, 5-MTHF) with an approach to this pathway that does not involve enzymatic action to control homocysteine metabolism. By ensuring efficient remethylation of homocysteine to methionine, 5-MTHF reduces vascular inflammation and supports the production of nitric oxide. Based on this, the active folate (5-MTHF) from PT Simex Pharmaceutical Indonesia is delivered in its bioavailable form to enhance endothelial integrity, stabilize vascular function, and provide comprehensive cardiovascular support.
References :
